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Abstract Asynchronously growing Chinese hamster ovary
(CHO) cells treated with the pro-drug, L-lactone ring form of
lovastatin were arrested in G1-phase. Subsequent removal of
lovastatin resulted in the synchronous entry of cells into S-phase
regardless of the presence of mevalonic acid. Lovastatin-arrested
cells contained hypophosphorylated retinoblastoma protein (Rb)
and required serum mitogens to enter S-phase after lovastatin
removal, indicating that cell-cycle arrest is prior to the restriction
point (R-point). However, in contrast to quiescent cells, intact
nuclei prepared from lovastatin-arrested cells were competent for
DNA replication when introduced into Xenopus egg extracts.
Initiation of replication by Xenopus egg cytosol took place
specifically within the dihydrofolate reductase (DHFR) origin
locus, demonstrating that cells were arrested after the origin
decision point (ODP). We conclude that the L-lactone ring form
of lovastatin is an effective reagent with which to synchronize
CHO cells between the ODP and R-point, without resulting in
the withdrawal of cells from the cell-cycle into a quiescent
state. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Lovastatin inhibits 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase, preventing the reduction of HMG-
CoA to mevalonate, the rate limiting step in cholesterol bio-
synthesis [1,2]. Lovastatin has also been shown to synchronize
mammalian cells in G1-phase [3^6] but the mechanism of cell-
cycle arrest has remained a mystery. Cell-cycle arrest was
originally shown to be reversed by the addition of mevalonate
[3^6], suggesting that the mevalonate pathway plays an im-
portant role in G1-phase progression. In order to be e¡ective
in the inhibition of HMG-CoA reductase activity, lovastatin
must ¢rst be converted from its pro-drug, L-lactone ring form
to its dihydroxy open ring form [3^5,7,8]. However, a recent
report found that the pro-drug form of lovastatin, which does
not inhibit HMG-CoA reductase, inhibits the proteasome and
is considerably more active in arresting mammalian cells in
G1-phase than after conversion to the open form [8].
The stage of G1-phase at which lovastatin exerts its e¡ect is
also not clear. Some studies have suggested that cells are
arrested in early G1-phase, prior to the restriction point (R-
point) [3], while others have concluded that lovastatin arrested
cells in late G1-phase [9]. Our previous studies have charac-
terized several G1-phase hallmarks in Chinese hamster ovary
(CHO) cells that take place as cells exit mitosis after synchro-
nization by mitotic shake-o¡ (Fig. 1). In particular, we have
de¢ned a novel point when the speci¢c sequences at which
replication will initiate within the CHO DHFR locus are es-
tablished [10]. This point, termed the origin decision point
(ODP), was originally de¢ned by introducing nuclei from cells
synchronized at di¡erent times during G1-phase into a cell-
free replication system derived from Xenopus eggs. Replica-
tion initiates at dispersed sites with nuclei isolated from cells
synchronized prior to the ODP, whereas replication initiates
at the same speci¢c origin sites utilized in vivo with nuclei
isolated after the ODP [10]. The ODP was subsequently veri-
¢ed in vivo, in the absence of the Xenopus egg extract system,
demonstrating that it is a bona ¢de novel G1-phase event [11].
The ODP is independent of mitogen stimulation, and takes
place several hours prior to phosphorylation of the retinoblas-
toma tumor suppressor protein (Rb) and the restriction point
(R-point), the point at which entry into S-phase becomes in-
dependent of serum mitogens [11,12]. Hence, our studies dem-
onstrate the existence of at least three distinct stages of G1-
phase (Fig. 1): (I) the pre-ODP stage when cells have not yet
selected where replication will initiate, (II) the post-ODP stage
prior to the R-point, when origins have been selected but cells
may still withdraw from the cell-cycle into a state of quies-
cence, and (III) the period after the R-point during which cells
prepare for DNA synthesis. Here, we demonstrate that the
pro-drug form of lovastatin can e¡ectively synchronize CHO
cells during the post-ODP, pre-R-point stage of G1-phase,
without causing a withdrawal of cells from the cell-cycle
into a quiescent state.
2. Materials and methods
2.1. Cell culture and synchrony
CHOC 400 cells, a derivative of CHO cells in which the DHFR
gene has been ampli¢ed to approximately 1000 copies per cell by
stepwise selection in methotrexate [13], were cultured as described
[12]. Lovastatin (Sigma, M2147) was dissolved directly in 60% ethanol
and stored at 320‡C, preserving its L-lactone ring structure. We did
not have success in synchronizing greater than 80% of CHOC 400
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 1 3 5 - 9
*Corresponding author. Fax: (86)-21-6433 8357.
E-mail: wujr@sunm.shcnc.ac.cn
1 Also corresponding author. Fax: (1)-315-464-8750;
E-mail: gilbertd@mail.upstate.edu
FEBS 24240 26-10-00
FEBS 24240FEBS Letters 484 (2000) 108^112
cells in G1-phase with the activated, open ring form of lovastatin,
which was converted from the pro-drug form as described [4]. Asyn-
chronous cultures of CHOC 400 cells were treated with 5 WM lova-
statin pro-drug. Within 24 h cells began to round up in culture even
though 10% still remained in S-phase as measured by BrdU incorpo-
ration. By 48 h of treatment, approximately 40% of cells detached
from the tissue culture dish. 32 h incubation was found to be optimal
for synchrony without signi¢cant cell detachment. These observations
are consistent with those of Rao et al. [8], who showed that 5 WM of
lovastatin pro-drug was su⁄cient for G1-phase synchrony of a human
tumor cell line but that 10 WM resulted in signi¢cant apoptosis. To
release synchronized cells, lovastatin medium was removed, cells were
washed three times with DMEM medium and fresh medium was
added. In some experiments, fresh medium was supplemented at
this point with mevalonic acid (Sigma, M4667) at the indicated con-
centrations (Fig. 2). Mitotic synchrony was achieved as described [14].
2.2. Flow cytometry and immunohistochemistry
For £ow cytometry, cells were trypsinized and ¢xed with 70% etha-
nol. Cells were then resuspended with phosphate bu¡ered saline (PBS)
containing 1 mg/ml RNase A and incubated at 37‡C for 30 min.
1U106 cells were stained with 20 Wg/ml propidium iodide and ana-
lyzed for DNA content with a Becton Dickinson FACSII £ow cytom-
eter. In parallel experiments, aliquots of cells were labeled with 33
Wg/ml of BrdU for 30 min, and then stained with anti-BrdU anti-
bodies as described [15].
2.3. Immunoblotting
Cells were washed twice with PBS, and lysed directly on the dish in
loading bu¡er (50 mM Tris (pH 6.8), 100 mM DTT, 2% SDS, 10%
glycerol and 0.1% bromophenol blue). Cell lysates were scraped into
Eppendorf tubes, boiled in a water bath for 5 min and stored at
320‡C. Protein concentration was determined by acid precipitation
of proteins, followed by the Bio-Rad protein assay, according to
Bio-Rad instructions. Approximately 50 Wg of the cell lysates were
subjected to 6.5% SDS^PAGE gel. Proteins were transferred to an
Immobilon-P membrane, incubated with anti-Rb (C-15; Santa Cruz
Biotechnology) and detected by ECL as described [12].
2.4. Preparation of intact nuclei and in vitro replication in Xenopus egg
extracts
Cells were permeabilized with digitonin on ice for 5 min, and the
percentage of intact nuclei were measured by £uorescence microscopy
as described [14]. Xenopus egg extracts were prepared as described
[14]. Intact nuclei were incubated with Xenopus egg extracts (17 000
nuclei per Wl extract) in the presence or absence of 3 mM 6-dimeth-
ylaminopurine (6-DMAP) at 21‡C, as described [14]. The fraction of
DNA that replicated was measured by acid precipitation as described
[14].
2.5. The early labeled fragment hybridization (ELFH) assay for
mapping replication origin sites
The ELFH assay has been described in detail [14], with subsequent
modi¢cations [16]. Brie£y, intact nuclei were incubated with Xenopus
egg extracts (17 000 nuclei per Wl extract) in the presence of aphidico-
lin (100 Wg/ml) at 21‡C for 2 h. Nuclei were then washed free of
extract and aphidicolin and nascent DNA synthesized close to origin
sites was pulse labeled in vitro with [K-32P]dATP. Radiolabeled DNA
was then isolated, sheared to small fragments and hybridized to a
panel of probes spanning 120 kb of the DHFR locus, which were
immobilized on nylon membranes. The relative amounts of hybridi-
zation of nascent DNA to each of these probes was then normalized
for probe size, dATP content and hybridization e⁄ciency as described
[14], and then plotted vs. map position to give a curve describing the
relative frequency of initiation at di¡erent sites throughout the DHFR
locus.
3. Results and discussion
3.1. The pro-drug form of lovastatin arrests CHO cells in
G1-phase, prior to the R-point
Despite several attempts, we were not successful in synchro-
nizing greater than 80% of CHOC 400 cells in G1-phase with
the activated, open ring form of lovastatin (not shown). Since
it was recently reported that the pro-drug form of lovastatin
may be more e¡ective at synchronizing mammalian cells in
G1-phase [8], we treated CHOC 400 cells with the pro-drug
form of lovastatin, which does not inhibit HMG-CoA reduc-
tase [8]. After 32 h exposure to lovastatin, less than 5% re-
mained in S-phase (as measured by BrdU incorporation) and
£ow cytometry analysis indicated that greater than 90% were
in G1/G0-phase (Fig. 2). To determine whether mevalonic acid
was necessary to release cells from lovastatin arrest, lovastatin
synchronized cells were transferred to fresh medium contain-
ing various concentrations of mevalonic acid (Fig. 2). Results
revealed that the presence of mevalonic acid had no in£uence
on progression of the cell-cycle after release from lovastatin.
Together, these data are consistent with those reported by
Rao et al. [8], suggesting that lovastatin does not inhibit the
cell-cycle through an e¡ect on HMG-CoA reductase but
through an independent mechanism dependent on the pro-
drug form of lovastatin. Previous results reporting cell syn-
chrony with the open ring form of lovastatin were likely due
to the fact that preparations of lovastatin after chemical con-
version to the open form are still signi¢cantly contaminated
with the L-lactone pro-drug [8].
Having demonstrated e⁄cient synchrony of CHOC 400
cells with the lovastatin pro-drug, we ¢rst wanted to deter-
mine whether cell-cycle arrest was prior to the R-point. We
have previously shown that the R-point is coincident with
phosphorylation of the retinoblastoma (Rb) tumor suppressor
protein in cycling cells (Fig. 1 and [12]). Hence, extracts pre-
pared from lovastatin-arrested cells were analyzed by immu-
noblotting with an anti-Rb antibody. Results revealed that,
after 24 h of lovastatin treatment (when 10% of cells still
could be detected in S-phase, as BrdU-positive cells), both
phosphorylated and dephosphorylated forms of Rb were de-
tectable whereas after 32 h, only the unphosphorylated form
of Rb was detected (Fig. 3A). After release from lovastatin
arrest, Rb phosphorylation was not observed for 6^9 h. Con-
Fig. 1. G1-phase hallmarks in CHOC 400 cells. The assembly of a
nuclear envelope [10,21], including a complete nuclear membrane
and lamina takes place within approximately 45 min after meta-
phase. Coincident with nuclear envelope formation is the association
of Mcm proteins with chromatin [22], a hallmark of pre-replication
complex (pre-RC) assembly and the transition to replication compe-
tence (often referred to as replication ‘licensing’). Over the next 60^
90 min, DNA sequences are gradually re-positioned within the nu-
cleus and, by 2 h after mitosis, the program for the order in which
chromosomal segments will be replicated is established [21] (timing
decision point; TDP). Between 3 and 4 h after metaphase cells pass
through the origin decision point (ODP), when the speci¢c sequen-
ces at which replication will initiate within the CHO DHFR locus
are established [10]. Phosphorylation of the retinoblastoma tumor
suppressor protein (Rb) takes place 6^8 h after metaphase, coinci-
dent with the R-point [12]. Within 2 h after passage through the R-
point, cyclin A protein accumulates [12], DNA synthesis proteins
RPA and PCNA associate with replication origins [22], and DNA
synthesis begins (approximately 50% of cells enter S-phase at 10 h
after metaphase; [10^12]).
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sistent with our previous results [12], 50% of cells entered S-
phase 2^3 h after Rb phosphorylation (Fig. 3B).
Since the R-point is de¢ned as a transition from serum de-
pendent to serum independent entry into S-phase, we exam-
ined whether the entry into S-phase after release from lova-
statin arrest required serum mitogens. Cells were released
from a lovastatin arrest and shifted to serum-free medium
at various times thereafter. All cultures were collected at 15
h after release, pulse labeled with BrdU, and the percentage of
cells that had entered S-phase was evaluated (Fig. 3C). Re-
sults revealed that lovastatin-arrested cells required serum for
entry into S-phase and gradually passed through a transition
to serum independent entry into S-phase 6^9 h after release
from the lovastatin block. This transition coincides with the
time of Rb phosphorylation under these conditions. We con-
clude from these experiments that the lovastatin arrest point is
upstream of the R-point.
3.2. Cells arrested by lovastatin are replication competent
Cells deprived of growth factors or exposed to inhibitors of
protein synthesis during G1-phase exit the cell-cycle and enter
a state of quiescence termed G0 [1]. Since G0 and G1 cells
both harbor unreplicated genomes, the experiments described
in Figs. 2 and 3 cannot distinguish whether cells arrested by
lovastatin have exited the cell-cycle and entered G0, or
whether they have remained in G1-phase. Recent studies
have demonstrated that intact nuclei from quiescent cells are
not competent for DNA replication when introduced into
Xenopus egg extracts [12,17,18], whereas nuclei collected dur-
ing G1-phase initiate DNA replication e⁄ciently in these same
extracts [10,12]. To determine whether nuclei from lovastatin-
arrested cells are replication competent, CHOC 400 cells were
treated with the pro-drug form of lovastatin for 32 h. Aliquots
of these cells were released in fresh medium for 2 or 6 h or
remained arrested. Intact nuclei were then prepared from each
of these samples, introduced into a Xenopus egg extract, and
the e⁄ciency of DNA replication was evaluated. Results (Fig.
4) revealed that the e⁄ciency of DNA replication with nuclei
from cells in the lovastatin-arrested state (0 h) was indistin-
guishable from that with nuclei isolated from cells released for
2 or 6 h. Both the e⁄ciency of DNA replication and the
length of the lag period before the onset of in vitro DNA
synthesis was similar to that observed in our previous studies
with nuclei from cells synchronized in G1-phase after mitotic
selection [10,12,14]. By contrast, DNA synthesis was almost
undetectable within nuclei from these same cells after they
were arrested in G0 by serum or isoleucine deprivation [12].
Several characteristics of DNA synthesis with nuclei from
Fig. 2. CHO cells are arrested in a G1/G0-phase by the pro-drug of
lovastatin. Asynchronous cultures of CHOC 400 cells were incu-
bated in the absence (control) and presence (lovastatin) of 5 WM
pro-drug form of lovastatin for 32 h. Aliquots of lovastatin-arrested
cells were released for 16, 20 or 24 h in the absence or presence of
the indicated concentration of mevalonate. Cells were then harvested
and DNA content was analyzed by £ow cytometry.
Fig. 3. CHO cells are arrested by lovastatin with hypophosphory-
lated Rb. A: Cell lysates were prepared from cells treated with lova-
statin for 24 or 32 h and from cells treated for 32 h and released
for 3, 6, 9, 12, or 15 h and subjected to immunoblotting with an
anti-Rb antibody. Cell lysates from asynchronous cells (As.) were
also analyzed as a control. The unphosphorylated (pRb) and phos-
phorylated (ppRb) forms of Rb are indicated. B: Cells from A
treated with lovastatin for 32 h and released were pulse labeled with
BrdU for 30 min, ¢xed and stained with an anti-BrdU antibody.
The percentage of labeled nuclei at each time point was scored.
C: Lovastatin-arrested cells were released into complete medium. At
the indicated time, cells were washed in serum-free medium and fur-
ther incubated in serum-free medium. At 15 h after release, all cul-
tures were pulse labeled with BrdU and the percentage of cells that
had entered S-phase was evaluated as in B.
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lovastatin-arrested cells were consistent with the de novo ini-
tiation of DNA replication, rather than DNA repair synthesis
or the elongation of pre-primed templates within contaminat-
ing S-phase cells. First, pulse labeling lovastatin-arrested cells
in culture with BrdU prior to nuclear isolation revealed that
less than 5% of these cells were synthesizing DNA at the time
of nuclear isolation, whereas s 99% incorporated BrdUTP in
vitro, demonstrating that the DNA synthesis observed is de-
pendent upon the in vitro replication system. Second, in vitro
DNA synthesis did not begin until after a 10^30 min lag
period, which is required for the assembly of initiation com-
plexes within G1-phase nuclei, whereas DNA synthesis within
S-phase nuclei begins immediately upon contact with the ex-
tract [14,15]. Finally, in vitro DNA synthesis was sensitive to
6-DMAP (see Fig. 4), a protein kinase inhibitor that prevents
the initiation of DNA replication but not elongation or repair
synthesis [14,15,19]. Taken together, these results demonstrate
that lovastatin arrest does not result in the loss of replication
competence, strongly suggesting that lovastatin does not cause
cells to enter into a quiescent state similar to the G0 state of
serum-arrested cells. Further insight into the nature of the
lovastatin-arrested state will require the examination of pre-
replication complex proteins, cyclins, cyclin dependent kinases
(cdks), and cdk inhibitors.
3.3. Lovastatin arrests CHO cells in the post-ODP stage of
G1-phase
Fig. 3B shows that cells do not enter S-phase until 11^12 h
after release from lovastatin arrest. This length of time is at
least as great as the entire length of G1-phase (Fig. 1). This
could indicate that cells require a recovery period after lova-
statin treatment, or it could mean that cells are arrested very
early in G1-phase. Since we have determined several early G1-
phase hallmarks in CHOC 400 cells (Fig. 1), we were in a
good position to distinguish between these two possibilities.
We ¢rst examined whether lovastatin-arrested cells are in the
pre-ODP or post-ODP stages of G1-phase by mapping the
sites of initiation within the DHFR locus when nuclei are
introduced into Xenopus egg extracts [14]. Nuclei from lova-
statin-arrested cells and cells released from lovastatin arrest
for 6 h were introduced into a Xenopus egg extract containing
aphidicolin. Aphidicolin allows the initiation of replication
and the formation of short primers but prevents the processive
elongation of replication forks, resulting in the trapping of
nascent DNA strands close to their sites of initiation [14,15].
These nascent strands were then radioactively labeled and hy-
bridized to a panel of 18 probes distributed over a 120 kb
region within the DHFR locus [14,15]. Initiation sites within
the DHFR locus were then revealed by plotting the relative
amounts of label at each map position (Fig. 5). As a control
for cells in the pre-ODP stages of G1-phase, cells were
synchronized in mitosis and released into G1-phase for 2 h.
As shown in Fig. 5, initiation of DNA replication took place
within the DHFR origin locus with nuclei from lovastatin-
arrested cells as well as cells released from lovastatin arrest
for 6 h, whereas initiation sites were distributed throughout
the DHFR locus in nuclei from pre-ODP control cells. We
conclude that the lovastatin pro-drug arrests CHO cells in the
post-ODP stage of G1-phase.
In normal cycling cells, phosphorylation of Rb takes place
3^4 h after the ODP and entry into S-phase takes place 6^7 h
Fig. 4. Lovastatin-arrested cells are in a replication competent state.
Intact nuclei were prepared from lovastatin-arrested cells and from
cells released from lovastatin arrest for 6 h. Nuclei were then intro-
duced into a Xenopus egg extract supplemented with [K-32P]dATP in
either the absence (closed symbols) or presence (open symbols) of
3 mM 6-DMAP. The percentage of input DNA replicated was de-
termined at the indicated times by acid precipitation [14].
Fig. 5. Lovastatin arrests CHO cells in the post-ODP stage of G1-
phase. Intact nuclei were prepared from lovastatin-arrested cells
(squares) and from cells released from lovastatin arrest for 6 h (tri-
angles). Nuclei were then introduced into a Xenopus egg extract and
the sites of initiation were evaluated using the ELFH assay (Section
2). The relative amounts of hybridization of the earliest labeled nas-
cent DNA to each probe from the DHFR locus are plotted against
the map position of each probe. As a control, intact pre-ODP nuclei
(circles) were prepared from cells synchronized in mitosis and re-
leased into G1-phase for 2 h, as described [10,12,14]. Shown are the
mean values from three independent experiments and the standard
deviation of the mean.
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after the ODP (Fig. 1). Clearly, lovastatin-arrested cells,
which take 11^12 h to enter S-phase after release (Fig. 3B)
yet are arrested in the post-ODP stage of G1-phase (Fig. 5),
must require several hours to recover from the e¡ects of the
drug. Since lovastatin arrest does not result in the entry of
cells into a quiescent state (Fig. 4), what might be the basis of
this recovery period? Other investigators have shown that
lovastatin induces the disassembly of actin stress ¢bers within
human mesangial cells within 24 to 48 h [20]. We observed
that CHOC 400 cells treated with lovastatin are rounder in
shape than untreated cells and re-£atten after release. We have
also shown that CHOC 400 cells become arrested in the post-
ODP stages of G1-phase when they are prevented from at-
taching to a solid substrate (S.M. Keezer and D.M. Gilbert,
unpublished observations). Hence, one possibility is that lov-
astatin-arrested cells need time to reform actin stress ¢bers
and return to a normal morphology before they can passage
through the R-point and enter S-phase.
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